Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya

Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya

Background. Tenofovir disoproxil fumarate (TDF) is commonly used in antiretroviral treatment (ART) and preexposure prophylaxis regimens. We evaluated the relationship of prenatal TDF use and growth outcomes among Kenyan HIV-exposed uninfected (HEU) infants. Materials and Methods. We included PCR-con...

Full description

Bibliographic Details
Main Authors:	Jillian Pintye, Agnes Langat, Benson Singa, John Kinuthia, Beryne Odeny, Abraham Katana, Lucy Nganga, Grace John-Stewart, Christine J. McGrath
Format:	Article
Language:	English
Published:	Hindawi Limited 2015-01-01
Series:	Infectious Diseases in Obstetrics and Gynecology
Online Access:	http://dx.doi.org/10.1155/2015/276851

Similar Items

Prevalence and correlates of non-disclosure of maternal HIV status to male partners: a national survey in Kenya
by: John Kinuthia, et al.
Published: (2018-05-01)

Male partner antenatal clinic attendance is associated with increased uptake of maternal health services and infant BCG immunization: a national survey in Kenya
by: Beryne Odeny, et al.
Published: (2019-08-01)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
by: Chanie Wassner PharmD, BCCCP, BCIDP, et al.
Published: (2020-04-01)

Liquid chromatography metabolite profiling of tenofovir disoproxil fumarate
by: Kokil Sachin, et al.
Published: (2009-01-01)

The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients
by: Selcen Korkmaz, et al.
Published: (2018-09-01)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021-07-01)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
by: Nicholas T. Funderburg, et al.
Published: (2016-11-01)

Effects of Hydrochlorothiazide on Tenofovir Disoproxil Fumarate-Induced Nephrotoxicity in Rats
by: Iman G.Al-Rakhat, et al.
Published: (2019-12-01)

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
by: J Jones, et al.
Published: (2010-05-01)

Formulation, development and assessment of tenofovir disoproxil fumarate-loaded pellets
by: Dube, Tawanda
Published: (2015)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
by: Andrew Hill, et al.
Published: (2018-04-01)

Evaluation of genotoxic activity of tenofovir disoproxil fumarate in human peripheral lymphocytes
by: Kubra Kurt, et al.
Published: (2016-06-01)

Latest progress in treatment of chronic hepatitis B with tenofovir disoproxil fumarate
by: ZHANG Yue
Published: (2015-04-01)

Safety of atazanavir/ritonavir with tenofovir disoproxil fumarate in HIV-infected adolescents
by: T. Bunupuradah, et al.
Published: (2014-04-01)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
by: Linn Hermansson, et al.
Published: (2019-01-01)

Review: Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B
by: Andrés Duarte-Rojo, et al.
Published: (2010-03-01)

Stress Studies of Tenofovir Disoproxil Fumarate by HPTLC in Bulk Drug and Pharmaceutical Formulation
by: Shweta Havele, et al.
Published: (2012-01-01)

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
by: Wissam K. Kabbara, et al.
Published: (2015-09-01)

Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate
by: Kate Braithwaite, et al.
Published: (2021-08-01)

Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate
by: Tim R. Cressey, et al.
Published: (2020-08-01)

Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
by: Calvin Q Pan, et al.
Published: (2021-01-01)

Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B
by: Daiki Aomura, et al.
Published: (2020-10-01)

Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
by: Ping Zhang, et al.
Published: (2018-08-01)

New simple spectrophotometric method for determination of the antiviral mixture of emtricitabine and tenofovir disoproxil fumarate
by: Heba K. Ashour, et al.
Published: (2017-05-01)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
by: Squillace N, et al.
Published: (2020-12-01)

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors
by: Pontrelli Giuseppe, et al.
Published: (2012-01-01)

Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Setting
by: The Staff
Published: (2014-01-01)

Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.
by: Calvin Q Pan, et al.
Published: (2014-01-01)

Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Setting.
Published: (2014-01-01)

Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya
by: Owino F, et al.
Published: (2013-11-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.
by: Kuo-Hsiung Yang, et al.
Published: (2014-01-01)

Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance
by: Yu-Yu Hsiao, et al.
Published: (2021-08-01)

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV
by: Laura Waters, et al.
Published: (2021-03-01)

Increase in bone turnover markers in HIV patients treated with tenofovir disoproxil fumarate combined with raltegravir or efavirenz
by: Yonatan Oster, et al.
Published: (2020-12-01)

Development and validation of a stability-indicating lc method for the determination of tenofovir disoproxil fumarate in pharmaceutical formulation
by: Shweta Havele, et al.
Published: (2012-12-01)

Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study
by: Kowthar Salman Hassan, et al.
Published: (2019-05-01)

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
by: Suzuki F, et al.
Published: (2014-06-01)

Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service
by: Dane Turner, et al.
Published: (2019-12-01)

Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load
by: Jun-Ze Chen, et al.
Published: (2017-06-01)